Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: A meta-analysis

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Bo, Lulong ^a   Wang, Fei ^a   Zhu, Jiali ^a   Li, Jinbao ^a   Deng, Xiaoming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTIINFECTIVE AGENT;

APACHE; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEPSIS; UNSPECIFIED SIDE EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOSPITAL MORTALITY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; TREATMENT OUTCOME;

EID: 79751531129     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10031     Document Type: Article

References (56)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
4. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005, 365:63-78. 10.1016/S0140-6736(04)17667-8, 15639681.
5. Russell JA. Management of sepsis. N Engl J Med 2006, 355:1699-1713. 10.1056/NEJMra043632, 17050894.
6. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. Crit Care Med 2008, 36:964-966. 10.1097/CCM.0B013E318165B886, 18431286.
7. Schefold JC. Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med 2010, 36:1810-1812. 10.1007/s00134-010-1965-7, 20652681.
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
9. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, Mougin B, Lepape A. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005, 33:31-38. discussion 236-237, 10.1097/01.CCM.0000150958.20209.A3, 15644645.
10. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 2006, 106:63-71. 10.1016/j.imlet.2006.04.010, 16765452.
11. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183. 10.1007/s00134-006-0204-8, 16741700.
12. Heidecke CD, Weighardt H, Hensler T, Bartels H, Holzmann B. [Immune paralysis of T-lymphocytes and monocytes in postoperative abdominal sepsis. Correlation of immune function with survival]. Chirurg 2000, 71:159-165. 10.1007/s001040050028, 10734584.
13. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001, 163:316-321.
14. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78. 10.2119/2007-00102.Monneret, 2078557, 18026569.
15. Schefold JC, Hasper D, Volk HD, Reinke P. Sepsis: time has come to focus on the later stages. Med Hypotheses 2008, 71:203-208. 10.1016/j.mehy.2008.03.022, 18448264.
16. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 2007, 280:21-27. discussion 27-36, 160-164, full_text, 17380786.
17. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005, 78:325-337. 10.1189/jlb.0105017, 15817707.
18. Monneret G, Debard AL, Venet F, Bohe J, Hequet O, Bienvenu J, Lepape A. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003, 31:2068-2071. 10.1097/01.CCM.0000069345.78884.0F, 12847405.
19. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891. 10.1038/nature01326, 12490963.
20. Hoesel LM, Gao H, Ward PA. New insights into cellular mechanisms during sepsis. Immunol Res 2006, 34:133-141. 10.1385/IR:34:2:133, 16760573.
21. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166:6952-6963.
22. Volk HD, Reinke P, Falck P, Staffer G, v Backer R. Diagnostic value of an immune monitoring program for the clinical management of immunosuppressed patients with septic complications. Clin Transplant 1989, 3:246-252.
23. Schefold JC, Hasper D, Reinke P, Monneret G, Volk HD. Consider delayed immunosuppression into the concept of sepsis. Crit Care Med 2008, 36:3118. 10.1097/CCM.0b013e31818bdd8f, 18941324.
24. Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 2002, 32:143-148. 10.1046/j.1445-5994.2002.00195.x, 11951925.
25. Flohe S, Borgermann J, Dominguez FE, Majetschak M, Lim L, Kreuzfelder E, Obertacke U, Nast-Kolb D, Schade FU. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock 1999, 12:17-24. 10.1097/00024382-199907000-00003, 10468047.
26. Flohe S, Lendemans S, Selbach C, Waydhas C, Ackermann M, Schade FU, Kreuzfelder E. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 2003, 31:2462-2469. 10.1097/01.CCM.0000089640.17523.57, 14530752.
27. Haberstroh J, Breuer H, Lucke I, Massarrat K, Fruh R, Mand U, Hagedorn P, Brunnberg L, von Specht BU. Effect of recombinant human granulocyte colony-stimulating factor on hemodynamic and cytokine response in a porcine model of Pseudomonas sepsis. Shock 1995, 4:216-224. 10.1097/00024382-199509000-00011, 8574758.
28. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992, 33:679-682.
29. Goya T, Torisu M, Doi F, Yoshida T. Effects of granulocyte colony stimulating factor and monobactam antibiotics (Aztreonam) on neutrophil functions in sepsis. Clin Immunol Immunopathol 1993, 69:278-284. 10.1006/clin.1993.1181, 7694816.
30. Eichacker PQ, Waisman Y, Natanson C, Farese A, Hoffman WD, Banks SM, MacVittie TJ. Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 1994, 77:2366-2373.
31. Carr R, Modi N, Doré C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, (3):CD003066.
32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W264.
33. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002, 31:150-153. 10.1093/ije/31.1.150, 11914311.
34. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
35. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
36. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. , http://www.cochrane.org/training/cochrane-handbook
37. Nelson S, Belknap SM. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. The Journal of Infectious Diseases 1998, 178:1075-1080. 10.1086/515694, 9806037.
38. Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, Fotheringham N, Welch W, Milwee S, Root R. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. Journal of Infectious Diseases 2000, 182:970-973. 10.1086/315775, 10950800.
39. Tanaka H, Nishino M, Nakamori Y, Ogura H, Ishikawa K, Shimazu T, Sugimoto H. Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 2001, 51:1110-1116. 10.1097/00005373-200112000-00016, 11740262.
40. Wunderink RG, Leeper KV, Schein R, Nelson S, DeBoisblanc BP, Fotheringham N, Logan E. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001, 119:523-529. 10.1378/chest.119.2.523, 11171733.
41. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002, 166:138-143. 10.1164/rccm.2009005, 12119223.
42. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S, . Pneumonia Sepsis Study G Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Critical Care Medicine 2003, 31:367-373. 10.1097/01.CCM.0000048629.32625.5D, 12576938, Pneumonia Sepsis Study G.
43. Hartmann P, Lammertink J, Mansmann G, Hübel K, Salzberger B, Stützer H, Engert A, Fätkenheuer G. A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. European Journal of Medical Research 2005, 10:29-35.
44. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005, 127:2139-2150. 10.1378/chest.127.6.2139, 15947332.
45. Orozco H, Arch J, Medina-Franco H, Pantoja JP, González QH, Vilatoba M, Hinojosa C, Vargas-Vorackova F, Sifuentes-Osornio J. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Archives of Surgery 2006, 141:150-153. discussion 154, 10.1001/archsurg.141.2.150, 16490891.
46. Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, Stephens DP, Day NP, White NJ, Chaowagul W, Currie BJ, Peacock SJ. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clinical Infectious Diseases 2007, 45:308-314. 10.1086/519261, 17599307.
47. Stephens DP, Thomas JH, Higgins A, Bailey M, Anstey NM, Currie BJ, Cheng AC. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008, 36:448-454. 10.1097/01.CCM.0B013E318161E480, 18216600.
48. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648. 10.1164/rccm.200903-0363OC, 19590022.
49. Cheng AC, Stephens DP, Currie BJ. Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2007, (2):CD004400.
50. Fumeaux T, Pugin J. Is the measurement of monocytes HLA-DR expression useful in patients with sepsis?. Intensive Care Med 2006, 32:1106-1108. 10.1007/s00134-006-0205-7, 16741699.
51. Tschoeke SK, Moldawer LL. Human leukocyte antigen expression in sepsis: what have we learned?. Crit Care Med 2005, 33:236-237. 10.1097/01.CCM.0000150835.66819.CA, 15644679.
52. Engelhard M, Brittinger G. Clinical relevance of granulocyte-macrophage colony-stimulating factor. Semin Oncol 1994, 21:1-4.
53. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000, 127:117-126. 10.1067/msy.2000.101584, 10686974.
54. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997, 350:855-859. 10.1016/S0140-6736(97)04495-4, 9310604.
55. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003, 29:646-651.
56. Schneider C, von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004, 239:75-81. 10.1097/01.sla.0000103062.21049.82, 1356195, 14685103.